Piper Sandler Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Soleno Therapeutics, with a price target of $145.00. The company’s shares closed yesterday at $57.98.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Rahimi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Soleno Therapeutics, and Crinetics Pharmaceuticals. According to TipRanks, Rahimi has an average return of 13.1% and a 41.74% success rate on recommended stocks.

Currently, the analyst consensus on Soleno Therapeutics is a Strong Buy with an average price target of $119.30, a 105.76% upside from current levels. In a report released on October 1, Stifel Nicolaus also maintained a Buy rating on the stock with a $115.00 price target.

Based on Soleno Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $32.66 million and a GAAP net loss of $4.71 million. In comparison, last year the company had a GAAP net loss of $21.85 million